ALG1-CDG is an autosomal recessive congenital disorder of glycosylation caused by biallelic pathogenic variants in ALG1. The first cases of ALG1-CDG were described in 2004, and the causative gene was identified at the same time. This disorder was originally designated CDG-IK, under earlier nomenclature for congenital disorders of glycosylation.[1] Clinically, individuals with ALG1-CDG have developmental delay, hypotonia, seizures and microcephaly.[2] Fewer than 60 cases of ALG1-CDG have been confirmed in published literature.[3] ALG1-CDG can be suspected based on clinical findings, and abnormal serum transferrin glycosylation test results.[3] Confirmation of the diagnosis can be performed based on sequence analysis of ALG1. The analysis of ALG1 is complicated by the presence of a pseudogene.[4] There are no specific treatments for ALG1-CDG, and most care consists of managing symptoms.[1][3]
| ALG1-CDG | |
|---|---|
| Other names | CDG-IK |
| Specialty | Medical genetics |
| Usual onset | birth |
| Causes | biallelic pathogenic variants in ALG1 |
| Treatment | none |
References
edit- ^ a b "# 608540 CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ik; CDG1K". Johns Hopkins University. Retrieved 2019-05-01.
- ^ "ALG1-CDG (CDG-Ik)". National Institutes of Health. Retrieved 2019-05-02.
- ^ a b c "Congenital Disorders of N-Linked Glycosylation and Multiple Pathway Overview". National Institutes of Health. Retrieved 2019-05-02.
- ^ Jaeken, Jaak; Lefeber, Dirk; Matthijs, Gert (2015). "Clinical utility gene card for: ALG1 defective congenital disorder of glycosylation". European Journal of Human Genetics. 23 (10): 1431–1431. doi:10.1038/ejhg.2015.9. ISSN 1018-4813. PMC 4592101.